Davis Polk advised the joint book-running managers in connection with the $86.25 million public offering of common stock of Coherus BioSciences, Inc.

Based in Redwood City, California, Coherus BioSciences, Inc. is a pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar) as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis.

The Davis Polk corporate team included partner Alan F. Denenberg, associates Emily Roberts and Dylan Service and summer law clerk Ganiatu Afolabi. Partner Rachel D. Kleinberg and associate Yixuan Long provided tax advice. Partner Frank J. Azzopardi and associate Jason J. Bang provided intellectual property and technology advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post